辉瑞出售其在消费者健康公司Haleon剩余的7%股份，价值超过30亿美元-动脉网

Pfizer Offloads Its Last 7% Stake In Consumer Health Haleon For Over $3 Billion

benzinga 等信源发布 2025-03-19 10:40



可切换为仅中文







On Wednesday, US drug company

周三，美国制药公司

Pfizer Inc

辉瑞公司

PFE

辉瑞公司

sold its entire stake in

出售了其全部股份在

Haleon Plc

赫力昂公司

HLN

to institutional investors and the consumer healthcare firm at 385 pence per share ($5.00).

向机构投资者和消费者医疗保健公司每股385便士（5.00美元）。

Under the deal, Haleon agreed to purchase approximately 44 million ordinary shares at 385 pence from Pfizer off-market for an aggregate consideration of approximately 170 million pounds, or $220 million.

根据协议，Haleon同意以每股385便士的价格从辉瑞公司场外购买约4400万股普通股，总金额约为1.7亿英镑（2.2亿美元）。

Also Read:

另请阅读：

Pfizer’s Direct-To-Consumer Model Faces Scrutiny From US Senators

辉瑞的直接面向消费者的模式受到美国参议员的质疑

Pfizer has

辉瑞公司

sold

已售

approximately 618 million ordinary shares in Haleon to institutional investors at 385 pence per share, raising gross sale proceeds of approximately 2.4 billion pounds, or $3.1 billion.

向机构投资者发售了约6.18亿股Haleon普通股，每股售价385便士，筹集了约24亿英镑（或31亿美元）的总销售收益。

After the off-market purchase and Pfizer’s offering to institutional investors, Pfizer’s interest in Haleon’s issued ordinary shares with voting rights is

在场外购入以及辉瑞向机构投资者发出要约后，辉瑞对Haleon已发行的具有投票权的普通股的兴趣是

expected

预期的

to reduce from approximately 7.3% to nil.

将从大约7.3%减少到零。

Brian McNamara,

布赖恩·麦克纳马拉，

CEO of Haleon, commented: “Today’s transaction is an important milestone for the business and marks Pfizer fully exiting its stake in Haleon, having been at 32% at the time of demerger in July 2022. Our participation in the offering is consistent with our disciplined capital allocation priorities, and supports our commitment to deliver attractive returns for shareholders, underpinned by a strong investment grade balance sheet.

Haleon首席执行官评论道：“今天的交易对业务而言是一个重要的里程碑，标志着辉瑞在2022年7月分拆时持有的32%股份完全退出。我们参与此次发行符合我们严谨的资本配置优先事项，并支持我们为股东提供有吸引力回报的承诺，同时依托强劲的投资级资产负债表。”

Nearly three years on from demerger, Haleon is in a position of strength and is well placed to capitalize on the significant opportunities ahead.”.

“距离分拆近三年，Haleon 处于强势地位，有望充分利用未来的重大机遇。”

Settlement of the offering is expected to occur on March 21.

预计本次发行的结算将于3月21日进行。

In October 2024, Pfizer divested a $3.3 billion stake in Haleon, reducing its holding from 22.6% to 15% in the British

2024年10月，辉瑞减持了其在Haleon的33亿美元股份，将其在这家英国公司的持股比例从22.6%降至15%。

consumer healthcare company

消费者医疗保健公司

。

In May 2024,

2024年5月，

GSK plc

葛兰素史克公司

GSK

葛兰素史克

confirmed the sale of 385.3 million shares in Haleon for $1.58 billion, fully exiting its

确认以 15.8 亿美元出售其持有的 3.853 亿股 Haleon 股份，完全退出其

position in Haleon

葛兰素史克旗下的赫力昂部门

。

In the fourth-quarter earnings release, Haleon projects 2025 organic revenue to grow between 4% and 6%. Haleon expects organic revenue and operating profit growth to be weighted towards the s

在第四季度财报发布中，Haleon预计2025年有机收入将增长4%至6%。Haleon预计有机收入和营业利润增长将更倾向于集中在下半年。

econd half of the year

年中下半年

。

Reuters notes that following Pfizer’s disposal,

路透社指出，继辉瑞公司处置之后，

BlackRock Inc’s

贝莱德集团的

BLK

块

unit will become Haleon’s largest shareholder with a more than 5% stake.

该部门将持有超过5%的股份，成为Haleon的最大股东。